pyrazines has been researched along with pevonedistat in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rolfe, M; Smith, PG; Soucy, TA | 1 |
| Harper, JW; Lim, HJ; Tan, MK | 1 |
| Bernal, L; Boise, LH; Chen, J; Gu, Y; Harvey, RD; Kaufman, JL; Lonial, S; Matulis, SM; Sun, SY; Torre, C | 1 |
| Hashimoto, K; Hibino, R; Inazuka, M; Ishikawa, T; Kuida, K; Morimoto, M; Smith, PG; Sumi, H; Yabuki, M; Yoshida, S | 1 |
| Dutta, R; Jeng, MY; Mannis, GN; Tan, IT; Zhang, TY | 1 |
1 trial(s) available for pyrazines and pevonedistat
| Article | Year |
|---|---|
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies.
Topics: Aged, 80 and over; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Disease-Free Survival; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Pyridines; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate | 2020 |
4 other study(ies) available for pyrazines and pevonedistat
| Article | Year |
|---|---|
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cullin Proteins; Cyclopentanes; Humans; NEDD8 Protein; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrimidines; RING Finger Domains; Signal Transduction; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Ubiquitins | 2009 |
SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
Topics: Basic Helix-Loop-Helix Transcription Factors; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Chromatin; Cyclopentanes; Epigenesis, Genetic; F-Box Proteins; Gene Expression Regulation; HEK293 Cells; HeLa Cells; Histone Demethylases; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Mass Spectrometry; Methylation; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Pyrazines; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Ubiquitination | 2011 |
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans; Multiple Myeloma; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Ubiquitin-Activating Enzymes; Up-Regulation | 2014 |
An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclopentanes; Dose-Response Relationship, Drug; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Mice; NEDD8 Protein; Neoplasms, Experimental; Oligopeptides; Pyrazines; Pyrimidines; Treatment Outcome; Ubiquitins | 2016 |